Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-Rad ABLTS:0R44 77 Debt-to-Equity is 0.03 as of Jun. 2026, which is at its 10-year median of 0.03. GuruFocus rates LTS:0R44 with a GF Score™ of 77/100 and a GF Value™ of kr33.62 (Fairly Valued). The stock has 3 warning signs investors should review. Among 697 Medical Devices & Instruments companies, C-Rad AB ranks better than 89.38% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for C-Rad AB's Debt-to-Equity or its related term are showing as below:
LTS:0R44'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.24
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of C-Rad AB was 0.24. The lowest was 0.00. And the median was 0.03.
LTS:0R44's Debt-to-Equity is ranked better than 89.38% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs LTS:0R44: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
C-Rad AB Debt-to-Equity Related Terms
C-Rad AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, C-Rad AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (LTS:0R44) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on C-Rad AB and its competitors. This is near median its historical median of 0.03. According to the industry distribution chart, C-Rad AB ranks #74 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 10.6%.
Is C-Rad AB's Debt-to-Equity too high?
C-Rad AB's current Debt-to-Equity of 0.03 is near median its 10-year median of 0.03. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. C-Rad AB's value of 0.03 is 87.5% below this industry median. Based on the distribution chart, C-Rad AB ranks #74 out of 697 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, C-Rad AB has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #74 out of 697 companies for Debt-to-Equity. This places C-Rad AB in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.24. C-Rad AB's value of 0.03 is 87.5% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.24, C-Rad AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Debt-to-Equity of 0.03 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Debt-to-Equity is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.62, compared to a current price of kr36.00 — trading 7.1% above its estimated fair value. The current Debt-to-Equity is 0.03, which is near median its 10-year median of 0.03 and 87.5% below the Medical Devices & Instruments industry median of 0.24. C-Rad AB's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr36.00 is trading 7.1% above its estimated GF Value™ of kr33.62.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
Debt-to-Equity: 0.03 (near median its 10-year median of 0.03)
GF Value™: kr33.62 vs. price of kr36.00 (7.1% above fair value)
Industry Position: 87.5% below the Medical Devices & Instruments median (#74 of 697)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
77GF Score
Get the complete analysis for LTS:0R44
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
